EUVIMEDEUVIMED entdecken
Crossref

Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway

Joo-Hwan Park, Hee Kyung Ahn, Hye Ryun Kim, Soyeon Kim, Keon-Uk Park, Tak Yun, Hyo Jung Kim, Sang-Cheol Lee, Sang Hee Cho, Sang-Gon Park, Bhumsuk Keam iD, Hwan Jung Yun iD

Head & Neck · 2026

DOI: 10.1002/hed.70165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Joo-Hwan Park und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Gachon University School of Medicine, Gil Medical Center, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Aminopyridines, Benzimidazoles, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF), Ministry of Health and Welfare, Republic of Korea, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HPV‐negative HNSCC is driven by cell cycle dysregulation, including CDK4/6 activation. Abemaciclib targets this pathway and may offer therapeutic benefits. This study aimed to identify biomarkers predicting abemaciclib efficacy.

Methods

In the NGS‐based TRIUMPH trial, patients with platinum‐refractory HNSCC harboring CDK4/6 pathway alteration received abemaciclib, classified as “long stable disease (SD)” (progression‐free survival [PFS] > 6 months) and “short SD” (PFS < 6 months). In this post hoc analysis, the genetic profiles were compared. In vitro studies were conducted to assess abemaciclib's antitumor effects in HNSCC cell lines.

Results

Among 23 patients, abemaciclib showed limited efficacy (overall response rate, 0%; disease control rate, 43.5%). CDKN2A deletion was significantly associated with long SD ( p = 0.0078), unlike CCND1 amplification and CDKN2A mutation. In vitro, CDKN2A ‐deleted cell lines showed greater sensitivity to abemaciclib.

Conclusions

Although abemaciclib resulted in limited tumor regression, CDKN2A deletion may be a predictive biomarker for prolonged disease stabilization. Further investigations on genomically selected populations and combination strategies are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesBenzimidazolesCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckNeoplasm Recurrence, LocalHumansFemaleBiomarkers, TumorMaleMutationCyclin-Dependent Kinase Inhibitor p16Cell Line, TumorAntineoplastic AgentsCyclin D1

Stichwörter der Autor:innen

CDKN2ATRIUMPHabemaciclibbiomarkerhead and neck squamous cell carcinoma (HNSCC)

Substanzen

abemaciclibAminopyridinesBenzimidazolesCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Biomarkers, TumorCDK6 protein, humanCDK4 protein, humanCyclin-Dependent Kinase Inhibitor p16Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Gachon University School of Medicine, Gil Medical Center, Incheon, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.

ORCID-Profile: Bhumsuk Keam, Hwan Jung Yun

Förderung

  • National Research Foundation of Korea (NRF)
  • Ministry of Health and Welfare, Republic of Korea
  • Ministry of Health and Welfare

Zitieren

APA

Park, J. H., Ahn, H. K., Kim, H. R., Kim, S., Park, K. U., Yun, T., Kim, H. J., Lee, S. C., Cho, S. H., Park, S. G., Keam, B., & Yun, H. J. (2026). Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway. Head & Neck. https://doi.org/10.1002/hed.70165

Vancouver

Park JH, Ahn HK, Kim HR, Kim S, Park KU, Yun T, et al. Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway. Head & Neck. 2026. doi:10.1002/hed.70165

BibTeX
@article{Park2026,
  author = {Park, Joo-Hwan and Ahn, Hee Kyung and Kim, Hye Ryun and Kim, Soyeon and Park, Keon-Uk and Yun, Tak and Kim, Hyo Jung and Lee, Sang-Cheol and Cho, Sang Hee and Park, Sang-Gon and Keam, Bhumsuk and Yun, Hwan Jung},
  title = {Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70165}
}
Kostenlos starten →